Association between Vancomycin-resistant enterococci bacteremia and ceftriaxone usage

Infection Control and Hospital Epidemiology

Volumn 33, Issue 7, 2012, Pages 718-724

  McKinnell, James A ^a,b   Kunz, Danielle F ^c   Chamot, Eric ^c   Patel, Mukesh ^d,e   Shirley, Rhett M ^d   Moser, Stephen A ^f   Baddley, John W ^d,e   Pappas, Peter G ^d   Miller, Loren G ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b TORRANCE MEMORIAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; ARTICLE; BLOODSTREAM INFECTION; DISEASE ASSOCIATION; DRUG UTILIZATION; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ALABAMA; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CROSS INFECTION; ENTEROCOCCUS; FEMALE; HOSPITALS, URBAN; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84863219106     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/666331     Document Type: Article

References (54)

1. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29(11):996-1011.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-317.
3. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58(2):163-170.
4. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32(8):470-485.
5. Scott RD. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention. Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention. Published March 2009. http://www.cdc.gov /HAI/pdfs/hai/Scott_CostPaper.pdf. Accessed November 5, 2011.
6. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007;122(2):160-166.
7. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162(19):2223-2228.
8. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003; 24(4):251-256.
9. Reik R, Tenover FC, Klein E, McDonald LC. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn Microbiol Infect Dis 2008;62(1):81-85.
10. Song JH, Ko KS, Suh JY, et al. Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype. J Antimicrob Chemother 2008;61(4): 838-844.
11. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41(3):327-333.
12. Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000;30(3): 466-472.
13. Lucas GM, Lechtzin N, PuryearDW, Yau LL, FlexnerCW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998;26(5):1127-1133.
14. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 2001; 135(7):484-492.
15. Bhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and-susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000;36(3): 145-158.
16. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007;35(10 suppl 2):S165-S193.
17. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1-12.
18. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23(5):1020-1025.
19. Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43(2):261-266.
20. Montecalvo MA, Jarvis WR, Uman J, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999;131(4): 269-272.
21. Smith DW. Decreased antimicrobial resistance after changes in antibiotic use. Pharmacotherapy 1999;19(8 pt 2):129S-132S; discussion 133S-137S.
22. Manzella J, Benenson R, Pellerin G, et al. Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia. Infect Control Hosp Epidemiol 2000;21(12):789-791.
23. May AK, Melton SM, McGwin G, Cross JM, Moser SA, Rue LW. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock 2000;14(3):259-264.
24. Nourse C, Byrne C, Murphy H, Kaufmann ME, Clarke A, Butler K. Eradication of vancomycin resistant Enterococcus faecium from a paediatric oncology unit and prevalence of colonization in hospitalized and community-based children. Epidemiol Infect 2000;124(1):53-59.
25. Puzniak LA, Mayfield J, Leet T, Kollef M, Mundy LM. Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit. Clin Infect Dis 2001;33(2):151-157.
26. Lautenbach E, LaRosa LA, Marr AM, Nachamkin I, Bilker WB, Fishman NO. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis 2003;36(4): 440-446.
27. Loeffler JM, Garbino J, Lew D, Harbarth S, Rohner P. Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units. Scand J Infect Dis 2003;35(11-12):843-850.
28. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38(suppl 4): S341-S345.
29. Empey KM, Rapp RP, Evans ME. The effect of an antimicrobial formulary change on hospital resistance patterns. Pharmacotherapy 2002;22(1):81-87.
30. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343(26): 1925-1932.
31. Donskey CJ, Hoyen CK, Das SM, Helfand MS, Hecker MT. Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002;23(8):436-440.
32. Paterson DL, Muto CA, Ndirangu M, et al. Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemother 2008;52(2):465-469.
33. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on persistence of vancomycinresistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 1999;180(2):384-390.
34. Lakticova V, Hutton-Thomas R, Meyer M, Gurkan E, Rice LB. Antibiotic-induced enterococcal expansion in the mouse intestine occurs throughout the small bowel and correlates poorly with suppression of competing flora. Antimicrob Agents Chemother 2006;50(9):3117-3123.
35. Rice LB, Lakticova V, Helfand MS, Hutton-Thomas R. In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enterococci. J Infect Dis 2004;190(12):2162-2166.
36. Rice LB, Hutton-Thomas R, Lakticova V, Helfand MS, Donskey CJ. b-Lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci. J Infect Dis 2004;189(6): 1113-1118.
37. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36(5):309-332.
38. Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135(3):175-183.
39. Kritsotakis EI, Christidou A, Roumbelaki M, Tselentis Y, Gikas A. The dynamic relationship between antibiotic use and the incidence of vancomycin-resistant Enterococcus: time-series modelling of 7-year surveillance data in a tertiary-care hospital. Clin Microbiol Infect 2008;14(8):747-754.
40. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46(6):1619-1628.
41. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32(7):1055-1061.
42. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycinresistant Enterococcus. Emerg Infect Dis 2002;8(8):802-807.
43. Ostrowsky BE, Venkataraman L, D'Agata EM, Gold HS, DeGirolami PC, Samore MH. Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. Arch Intern Med 1999;159(13): 1467-1472.
44. Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 1999;159(20):2461-2468.
45. de Bruin MA, Riley LW. Does vancomycin prescribing intervention affect vancomycin-resistant enterococcus infection and colonization in hospitals? a systematic review. BMC Infect Dis 2007;7:24.
46. Guggenbichler JP, Kofler J, Allerberger F. The influence of thirdgeneration cephalosporins on the aerobic intestinal flora. Infection 1985;13(suppl 1):S137-S139.
47. Donskey CJ, Hume ME, Callaway TR, Das SM, Hoyen CK, Rice LB. Inhibition of vancomycin-resistant enterococci by an in vitro continuous-flow competitive exclusion culture containing human stool flora. J Infect Dis 2001;184(12):1624-1627.
48. Winston LG, Charlebois ED, Pang S, Bangsberg DR, Perdreau-Remington F, Chambers HF. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. Am J Infect Control 2004;32(8):462-469.
49. Bonten MJ, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998;158(10):1127-1132.
50. Aldeyab MA, Harbarth S, Vernaz N, et al. Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients. Antimicrob Agents Chemother 2009;53(5):2082-2088.
51. Kaier K, Frank U. Relationship between antibiotic consumption and Clostridium difficile-associated diarrhea: an epidemiological note. Antimicrob Agents Chemother 2009;53(10):4574-4575.
52. McKinnell JA, Powderly AL, Kunz DF, Patel M. Individual antimicrobials and risk of VRE colonization. Presented at: 48th Annual Meeting of the Infectious Diseases Society of America; Vancouver; October 21-24, 2010. Abstract 3365.
53. Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant Enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009;30(2): 184-186.
54. Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011;364(15):1407-1418.